COVID-19 infection, compared with influenza, is associated with increased myocarditis rates among adults in the United States.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

A study has found that, among women with breast cancer, aerobic exercise significantly decreases risk for cardiovascular disease.

Artificial intelligence (AI) can improve detection of congenital heart defects (CHDs) on routine prenatal ultrasounds.

The rescheduling of marijuana may remove regulatory hurdles and expand the breadth of research beyond pain management.

The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.

The Trump Administration’s censorship extends beyond federal websites and datasets to include research to be published in academic journals.

Propranolol is associated with a reduced risk for overall stroke among women with migraine, with a more pronounced protective effect for ischemic stroke.

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.

Patients that receive virtual cardiac rehabilitation have improved hospital admission and emergency department visit rates.

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

The majority of US adults use a device on a regular basis to monitor their heart health, but only 1 in 4 uses those data to have a conversation about their heart health with their doctor.